Your home base
Today on The Peptide Era
Pick up where you left off, see what actually changed, and gut-check a claim — in under a minute.
What changed
through 2026-07-01- Medicare starts covering GLP-1s for weight loss — the "Bridge" programA temporary Medicare demonstration (July 2026–Dec 2027) opens obesity coverage for GLP-1s like Wegovy, Zepbound and the new pill Foundayo, with a roughly $50 copay for eligible enrollees. First-ever Medicare pathway for weight-loss GLP-1s — check the specifics against the official notice.
- Cash prices fall as manufacturer & TrumpRx deals roll outMost-favored-nation and direct-pay programs cut self-pay costs — injectables into the ~$245–350/month range and the oral options from ~$149/month. It reshapes the self-pay market just as large-scale compounded supply is being wound down.
- FDA extends the compounded-GLP-1 comment period to July 30The proposal to remove semaglutide and tirzepatide from the 503B bulks list isn't final — the public comment window was extended by 30 days and is still open.
- Microdosing keeps trending — the evidence hasn't movedSub-therapeutic 'microdosing' is everywhere on social media, but there's still no trial showing it works or is safe, and professional societies don't support it.
- CagriSema (GLP-1 + amylin) beats semaglutide in type 2 diabetes — published in The LancetNovo’s cagrilintide-plus-semaglutide combo showed greater HbA1c and weight reduction than semaglutide alone in the peer-reviewed REIMAGINE trials. Still investigational in the US, with an FDA decision expected later in 2026.
- ADA 2026: retatrutide’s full phase-3 data — up to ~28% weight lossThe triple agonist’s pivotal TRIUMPH-1 trial reported the highest weight loss yet for an incretin drug (about 28% at the top dose, with a real tolerability tail). Still investigational and not approved — not something sold to consumers today.
- Retatrutide phase-3 topline reportedThe triple agonist's pivotal obesity trial reported large weight loss. Still investigational and not approved — and anything sold to consumers as 'retatrutide' today is unregulated.
- FDA proposes excluding compounded semaglutide & tirzepatide from the 503B listCiting no 'clinical need' beyond cost, the FDA moved to further restrict large-scale compounding of the GLP-1 molecules — a big deal for anyone who relied on compounded supply.
- Survodutide (glucagon/GLP-1) posts obesity + liver-fat dataBoehringer’s dual agonist showed meaningful weight loss and, in a separate MASLD study, normalized liver fat in roughly 6 of 10 people — keeping its liver-disease (MASH) angle alive. Investigational.
- Orforglipron (Foundayo) approved — the first oral GLP-1 pillA once-daily non-peptide GLP-1 you swallow, with no food/water timing. Approval brings a list price and coverage — and a new wave of branded search.
- A useful negative: semaglutide did NOT slow Alzheimer’s (EVOKE)Two large phase-3 trials found oral semaglutide gave no benefit on cognitive decline in early Alzheimer’s. A clean, peer-reviewed reminder that “GLP-1 for everything” gets ahead of the evidence.